Hemanshu Shah (PhD)

Hemanshu Shah, Chief Business Officer, is an executive with more than 30 years’ experience, in both large pharmaceutical companies (Bristol-Myers Squibb, Johnson & Johnson and Astellas) and emerging biotechnology companies (GPC Biotech, Innate Pharma and Transgene). He is currently a member of the Supervisory Board of Modra Pharmaceuticals B.V.

Otto Kari (PhD)

Otto Kari, VP & Head of Antigen Business Unit, holds a Ph.D. in Pharmacy from the University of Helsinki, Finland. He has over 15 years of experience in pharmaceutical research and development, with advanced qualifications in R&D and technology management. During his Ph.D. and post-doctoral studies, he developed and set up novel and innovative methods and infrastructure for the study of biocorona formation on nanotechnological drug delivery systems and viruses.

Paul G Higham

Paul G Higham, Chief Executive Officer, is a seasoned healthcare industry expert with extensive leadership experience in both large pharmaceutical and biotech companies. He has over 15 years C-Suite Biotech company experience. During the last 10 years he has been CEO of two immuno-oncology development-stage companies. In more detail:

Hanne Cojoc (M.Sc. Tech)

Hanne Cojoc, QA Manager/Technical Scientist, holds an M.Sc. (Tech) in Bioengineering from Tampere University, Finland. She has gained broad QA experience ranging from pharmaceutical development to healthcare technology. Hanne has also extensive experience in bio-technical laboratory work in both the clinical and pre-clinical settings.